Tourmaline Bio Valuation
| TRML Stock | 25.66 0.38 1.46% |
At this time, the company appears to be undervalued. Tourmaline Bio has a current Real Value of USD31.21 per share. The regular price of the company is USD25.66. Our model measures the value of Tourmaline Bio from inspecting the company fundamentals such as Shares Outstanding of 25.64 M, number of shares shorted of 1.66 M, and Return On Equity of -0.32 as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Tourmaline Bio's valuation include:
Price Book 2.0797 | Enterprise Value 386.1 M | Enterprise Value Ebitda (281.95) |
Undervalued
Today
Please note that Tourmaline Bio's price fluctuation is not too volatile at this time. Calculation of the real value of Tourmaline Bio is based on 3 months time horizon. Increasing Tourmaline Bio's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Tourmaline stock is determined by what a typical buyer is willing to pay for full or partial control of Tourmaline Bio. Since Tourmaline Bio is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Tourmaline Stock. However, Tourmaline Bio's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 25.66 | Real 31.21 | Target 48.67 | Hype 26.97 |
The intrinsic value of Tourmaline Bio's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Tourmaline Bio's stock price.
Estimating the potential upside or downside of Tourmaline Bio helps investors to forecast how Tourmaline stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Tourmaline Bio more accurately as focusing exclusively on Tourmaline Bio's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Tourmaline Bio's intrinsic value based on its ongoing forecasts of Tourmaline Bio's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Tourmaline Bio's closest peers.
Tourmaline Bio Cash |
|
Tourmaline Valuation Trend
Knowing Tourmaline Bio's actual value is paramount for traders when making sound investment determinations. Using both Tourmaline Bio's enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Tourmaline Bio Total Value Analysis
Tourmaline Bio is at this time expected to have valuation of 386.1 M with market capitalization of 667.73 M, debt of 415 K, and cash on hands of . Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Tourmaline Bio fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
386.1 M | 667.73 M | 415 K |
Tourmaline Bio Asset Utilization
One of the ways to look at asset utilization of Tourmaline is to check how much profit was generated for every dollar of assets it reports. Tourmaline Bio has a negative utilization of assets of -0.24 %, losing USD0.002382 for each dollar of assets held by the company. Inadequate asset utilization indicates the company is being less effective with each dollar of assets it has. In other words, asset utilization of Tourmaline Bio shows how discouraging it operates for each dollar spent on its assets.Tourmaline Bio Ownership Allocation
Tourmaline Bio shows a total of 25.64 Million outstanding shares. The majority of Tourmaline Bio outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Tourmaline Bio to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Tourmaline Bio. Please pay attention to any change in the institutional holdings of Tourmaline Bio as this could imply that something significant has changed or is about to change at the company. Also note that roughly one million seven hundred thousand one hundred four invesors are currently shorting Tourmaline Bio expressing very little confidence in its future performance.Tourmaline Bio Profitability Analysis
Net Loss for the year was (42.12 M) with profit before overhead, payroll, taxes, and interest of 0.Tourmaline Bio Past Distributions to stockholders
About Tourmaline Bio Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Tourmaline Bio. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Tourmaline Bio based exclusively on its fundamental and basic technical indicators. By analyzing Tourmaline Bio's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Tourmaline Bio's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Tourmaline Bio. We calculate exposure to Tourmaline Bio's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Tourmaline Bio's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -33 K | -34.6 K |
A single share of Tourmaline Bio represents a small ownership stake in the entity. As a stockholder of Tourmaline, your percentage of company ownership is determined by dividing the number of shares you own by the total number of shares outstanding and then multiplying that amount by 100. Owning stock in a company generally confers both corporate voting rights and income from any dividends paid to the stock owner.
Tourmaline Bio Dividends Analysis For Valuation
Please note that Tourmaline Bio has scaled down on payment of dividends at this time. Retained Earnings is expected to rise to about (58.9 M) this year. Earnings Yield is expected to rise to -0.32 this year
There are various types of dividends Tourmaline Bio can pay to its shareholders, and the actual value of the dividend is determined on a per-share basis. It is to be paid equally to all of Tourmaline shareholders on a specific date, known as the payable date. The cash dividend is the most common type of dividend payment - it is the payment of actual cash from Tourmaline Bio directly to its shareholders. There are other types of dividends that companies can issue, such as stock dividends or asset dividends. When Tourmaline pays a dividend, it has no impact on its enterprise value. It does, however, lowers the Equity Value of Tourmaline Bio by the value of the dividends paid out.
Tourmaline Bio Growth Indicators
Investing in growth stocks can be very risky. If the company such as Tourmaline Bio does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 4.7 M |
Tourmaline Bio Current Valuation Indicators
Tourmaline Bio's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Tourmaline Bio's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Tourmaline Bio, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Tourmaline Bio's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Tourmaline Bio's worth.When determining whether Tourmaline Bio is a strong investment it is important to analyze Tourmaline Bio's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Tourmaline Bio's future performance. For an informed investment choice regarding Tourmaline Stock, refer to the following important reports: Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tourmaline Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For more information on how to buy Tourmaline Stock please use our How to buy in Tourmaline Stock guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tourmaline Bio. If investors know Tourmaline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tourmaline Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.49) | Return On Assets (0.24) | Return On Equity (0.32) |
The market value of Tourmaline Bio is measured differently than its book value, which is the value of Tourmaline that is recorded on the company's balance sheet. Investors also form their own opinion of Tourmaline Bio's value that differs from its market value or its book value, called intrinsic value, which is Tourmaline Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tourmaline Bio's market value can be influenced by many factors that don't directly affect Tourmaline Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tourmaline Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tourmaline Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tourmaline Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.